Lenvakast 10 mg (Lenvatinib)

Lenvakast 10mg 

Lenvakast 10 mg (Lenvatinib) is a prescription anti-cancer agent specifically indicated against Renal Cell Carcinoma (RCC) and Differentiated Thyroid Cancer (DTC). For kidney cancer (RCC), everolimus is used in combination with Lenvakast 10 mg to attain a sustainable efficacy. Whereas for thyroid cancer, Lenvakast 10 mg is favoured, if cancer cannot be removed by surgical operation.

Lenvakast 10 mg is taken orally with or without food. Preferably, it should be consumed at the same time each day. For kidney cancer (RCC), 18 mg (1 tablet of 10 mg and 2 tablets of 4 mg) is taken along with 5 mg (1 tablet) everolimus. While, for thyroid cancer (DTC), 24 mg (1 tablet of 4 mg and 2 tablets of 10 mg) is an ideal regimen.

In certain cases, due to the advent of severe side-effects or complications in the kidney or liver, the dosage could be reduced for the safety of the patients. The table below shows the recommended dosage reductions for Lenvakast 10 mg (Lenvatinib) in such conditions.

Note: The number of tablets is decided by the respective healthcare provider for safety purposes.

Side-effects associated with Lenvakast 10mg (Lenvatinib):

Most common side-effect: Diarrhea

Common side-effects associated with RCC:

• Cough
• Tiredness
• Vomiting
• Difficulty in breathing (Dyspnea)
• Nausea
• Pain in the stomach region (abdomen)
• Joint and muscle pain
• Bleeding
• Loss of weight and appetite
• Mouth sores
• Swelling on arms and legs
• Rashes

Common side-effects associated with DTC:

• Headache
• Tiredness
• Vomiting
• Nausea
• Pain in the stomach region (abdomen)
• Mouth sores
• Pain in the joints and muscles
• Loss of weight
• Itching or peeling of your skin
• Loss of appetite
• Hoarseness
• Rashes
• Redness

Note: Please refer your healthcare provider for more updates regarding Lenvakast (Lenvatinib), as it might show other side-effects as well.

When should Lenvakast 10 mg be avoided or taken cautiously?

It is important to inform your doctor regarding certain condition before the administration of Lenvakast 10mg (Lenvatinib), these include,

• Atypical connections between two sections of the gastrointestinal tract (Fistula) with abdominal pain
• Low levels of calcium in the blood (Hypocalcemia)
• Problems in healing the wounds
• Increased amounts of protein in the urine (Proteinuria)
• Severe bleeding through different forms including stools, urine, or cough and regions such as nose and vagina
• High blood pressure (Hypertension)
• History of blood clots, stroke, heart attack, or changes in vision
• Heart problems
• Kidney or liver complications with symptoms like jaundice, irregular bowel movements like dark-coloured urine or light-coloured stools, dizziness, and confusion
• High blood pressure (Hypertension)
• Heart problems with symptoms like shortness of breath (dyspnea) and swelling in the ankles
• History of blood clots, stroke, heart attack, or changes in vision with symptoms like severe chest pain, pain in the neck, back, or jaw, sudden events of headache or blurred vision, shortness of breath and numbness on the one side of the body
• Tear in the stomach or intestines (Perforation) with abdominal pain
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS) with symptoms like severe headache, seizures, weakness, confusion or blindness

Note: Lenvakast 10 mg is also available in these countries

(South East Asia, South America, Eastern Europe, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Poland, Republic of Kosovo, Republic of Moldova, Romania, Russia, Serbia, Slovak Republic and Slovenia, Malaysia, Indonesia, Philippines, Venezuela and Korea.) and many more…)